Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study-Reference-Cited by-同舟云学术

Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study

Published:2021-12-29 Issue: Volume: Page:
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Toulmonde Maud,Brahmi Mehdi,Giraud Antoine,Chakiba Camille,Bessede Alban,Kind Michèle,Toulza Emilie,Pulido Marina,Albert Sabrina^ORCID,Guégan Jean-Philippe,Cousin Sophie,Mathoulin-Pelissier Simone,Perret Raul^ORCID,Croce Sabrina^ORCID,Blay Jean-Yves^ORCID,Ray-Coquard Isabelle^ORCID,Floquet Anne,Italiano Antoine

Funder

ASTRA ZENECA

PharmaMar

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Sarcoma: Current Data and Promising Strategies;American Society of Clinical Oncology Educational Book;2024-06

2. Combination treatment with PD1/PDL-1 inhibitors for sarcomas: state of the art, next questions;Current Opinion in Oncology;2024-04-30

3. Impact of metronomic trabectedin combined with low-dose cyclophosphamide on sarcoma microenvironment and correlation with clinical outcome: results from the TARMIC study;Molecular Cancer;2024-02-19

4. Role of Immunotherapy in Sarcomas;International Journal of Molecular Sciences;2024-01-19

5. Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological Correlates;Clinical Cancer Research;2024-01-18